Investor Presentaiton slide image

Investor Presentaiton

LOVVOLUS HIGHLIGHTS A HIGHLY COMPETITIVE FILLER LINE • Evolysse™ - a first-generation cold technology Hyaluronic Acid line · 5 fillers in late-stage clinical development Indications including mid face, nasolabial folds, lips and eyes • In partnership with Symatese, developer of the latest generation of Restylane® products in the U.S. • RAISING 2028 REVENUE OUTLOOK FROM $500M TO $700M Increasing guidance by $200M in 2028 based on product launches in 2025, 2026 and 2027 A HIGHLY CAPITAL EFFICIENT AGREEMENT • Minimal short-term dilution delivering material long-term value accretion • Funded to profitability with $50M Pharmakon tranche • Leverage existing sales force, digital infrastructure, Evolus Rewards and co-branded media 769 D
View entire presentation